SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Pitt, W. A.
Right arrow Articles by Mazur, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pitt, W. A.
Right arrow Articles by Mazur, J. H.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Effect of Intravenous Nitroglycerin on Hemodynamics of Congestive Heart Failure

William A. Pitt

Department of Cardiology, Mercy Hospital and Medical Center, San Diego, California

Richard G. Friedman

Department of Cardiology, Mercy Hospital and Medical Center, San Diego, California

Steven A. Gross

Department of Cardiology, Mercy Hospital and Medical Center, San Diego, California

Jerrold Glassman

Department of Cardiology, Mercy Hospital and Medical Center, San Diego, California

Edward C. Keating

Department of Cardiology, Mercy Hospital and Medical Center, San Diego, California

John H. Mazur

Department of Cardiology, Mercy Hospital and Medical Center, San Diego, California

Intravenous nitroglycerin (IV-NTG) has gained wide use in the manage ment of critically ill patients, yet little is known regarding dose-response hemodynamics in man. Therefore, we studied 10 patients, all Class III or IV New York Heart Association Classification with pulmonary artery wedge pressures of 15 torr or greater. A special delivery system designed to prevent drug absorption Nitrostat® IV Infusion Kit was used and assessed. Multiple hemodynamic values were recorded before, during, and after the infusion. Administration of IV-NTG was started at 0.125 mcg/kg/min and was doubled every 15 minutes to a maximum dose of 2.0 mcg/kg/min. The infusion was stopped if the pulmonary artery wedge pressure dropped below 10 torr, or arterial pressure dropped below 90/60 torr, or if the mean artery pressure fell more than 10 torr, or if significant side effects occurred. Samples for blood levels were collected. Only one patient noted any untoward effects and he recovered quickly upon cessation of infusion. The mean infusion rate was 0.6125 mcg/kg/min. A significant drop in mean arterial blood pressure, mean pulmonary artery pressure, mean pulmonary artery wedge pressure, heart rate, and arterial oxygenation was noted. Cardiac output did not change significantly. Pulmonary vascular resistance index, as well as several other indices, decreased significantly in all patients.

Nitrostat IV® appears to be very safe and to work by dilating preload capacitance vessels, followed by a drop in arterial pressure without an adverse lowering of cardiac output.

Angiology, Vol. 33, No. 5, 294-301 (1982)
DOI: 10.1177/000331978203300502
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement